19967-55-6

Usage

Uses

Used in Pharmaceutical Research:
1-Bromo-3-methyl-2-butanone is used as a reagent in the preparation of pharmaceutical intermediates for the development of drugs, such as barbiturates and sedatives. Its chemical properties make it a valuable component in the synthesis of these medications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Bromo-3-methyl-2-butanone serves as a chemical intermediate, facilitating the production of other organic compounds. Its versatility in reactions contributes to the creation of a wide range of chemical products.
Used in the Food Industry:
1-Bromo-3-methyl-2-butanone is utilized as a flavoring agent, adding unique taste profiles to various food products. Its ability to dissolve in water and organic solvents makes it suitable for use in a variety of food applications.
However, it is important to note that 1-Bromo-3-methyl-2-butanone is a hazardous chemical and should be handled with caution to avoid potential health risks. Proper safety measures and handling procedures must be followed to ensure the safe use of 1-Bromo-3-methyl-2-butanone in its various applications.

InChI:InChI=1/C5H9BrO/c1-4(2)5(7)3-6/h4H,3H2,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 2736-37-0 isobutyryl bromide 
• 123-91-1 1,4-dioxane 
• 563-80-4 3-methyl-butan-2-one 
• 60-29-7 diethyl ether 
• 15481-39-7 dioxane dibromide 
• 79-30-1 isobutyryl chloride 
• 17510-45-1 2-(trimethylsilyloxy)-3-methyl-1-butene 
• 58369-66-7 1,1-dibromo-3-methyl-2-butanol 
• 69561-99-5 3-Methyl-1-trimethylsilanyl-butan-2-one 
• 1806-12-8 2-(1-pyrrolidinyl)-3-methyl-1-butene 
• 598-75-4 3-methyl-2-butanol 
• 1271-66-5 dimethyltitanocene 
• 21678-37-5 N,N,2-trimethylpropionamide 

Downstream Products

• 79932-20-0 2-Amino-4-isopropylthiazole 
• 32085-47-5 (3-Methyl-2-oxo-butyl)-triphenyl-phosphonium; bromide 
• 32272-52-9 4-isopropyl-2-methylthiazole 
• 32272-42-7 2-Aethyl-4-hydroxy-4-isopropyl-thiazolin-Δ2 
• 51513-41-8 2,7-dimethyl-octane-3,6-dione 
• 563-80-4 3-methyl-butan-2-one 
• 122657-50-5 1-(3-bromo-2-thiophenyl)-4-methyl-1E-penten-3-one 
• 96428-18-1 8-Benzyloxy-2-isopropyl-imidazo[1,2-a]pyridine 
• 3160-32-5 4-methyl-1-phenyl-1-penten-3-one 
• 122657-49-2 3-methyl-4E-decen-3-one 
• 119752-01-1 5-(4-bromophenyl)-5-hydroxy-2-methylpentan-3-one 
• 121077-68-7 (3-methyl-2-oxobutyl)triphenyl-arsonium bromide 
• 85656-45-7 2-(N-benzyl-N-methylamino)-4-(1-methylethyl)thiazole 
• 102670-65-5 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-[(3-methyl)-butan-2-on-1-yl]oxybenzamide 

Relevant academic research and scientific papers

A synthesis of orixiarine

A synthesis of the quinoline alkaloid, orixiarine was achieved starting from N-methylaniline and isopropyl methyl ketone.

Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents

Cyclin-dependent kinases (CDKs) are a family of Ser/Thr kinases involved in cell cycle and transcriptional regulation. CDK9 regulates transcriptional elongation and this unique property has made it a potential target for several diseases. Due to the conserved ATP binding site, designing selective CDK9 inhibitors has been challenging. Here we report our continued efforts in the optimization of 2,4,5-tri-substituted pyrimidine compounds as potent and selective CDK9 inhibitors. The most selective compound 30m was >100-fold selective for CDK9 over CDK1 and CDK2. These compounds showed broad anti-proliferative activities in various solid tumour cell lines and patient-derived chronic lymphocytic leukaemia (CLL) cells. Decreased phosphorylation of the carboxyl terminal domain (CTD) of RNAPII at Ser-2 and down-regulation of anti-apoptotic protein Mcl-1 were confirmed in both the ovarian cancer model A2780 and patient-derived CLL cells.

Enantioselective Nickel-Catalyzed anti-Arylmetallative Cyclizations onto Acyclic Ketones

Domino reactions involving nickel-catalyzed additions of (hetero)arylboronic acids to alkynes, followed by cyclization of the alkenylnickel intermediates onto tethered acyclic ketones to give chiral tertiary-alcohol-containing products in high enantioselectivities, are described. The reversible E/Z isomerization of the alkenylnickel intermediates enables overall anti-arylmetallative cyclization to occur. The ring system of the products are substructures of certain diarylindolizidine alkaloids.

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Diastereoselective Synthesis of Z-Alkenyl Disulfides from α-Thiophosphorylated Ketones and Thiosulfonates

We developed a simple and efficient method for the synthesis of functionalized unsymmetrical Z-alkenyl disulfides under mild conditions in moderate to good yields. The designed method is based on the reaction of α-thiophosphorylated carbonyl compounds with thiotosylates in the presence of a base. The developed method allows the preparation of unsymmetrical Z-alkenyl disulfides bearing additional hydroxy, carboxy, or ester functionalities. (Figure presented.).

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Pyrimidinone Derivatives as Antimalarial Agents

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

CXCR4 Receptor Antagonists

Disclosed are compounds that are antagonists of the CXCR4 receptor.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.